Answer
Subcutaneous pegzilarginase (Loargys) caused injection-site pain, erythema, swelling, irritation and rash in 13.6% (6/44) of treated patients; reactions were mild and resolved spontaneously or with standard medical care without dose interruption.
Sources for this answer
- Loargys 5 mg/ml solution for injection/infusionImmedica · emc · SmPC §4.8 Undesirable effects · Version 4Document updated
Sources checked